. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107

Table 2.

Study Characteristics of Nonrandomized Trials

Study	Design	No.	Patient	Intervention	Median Follow-Up, mo
Inoue et al., 2009³⁹ (NEJ001)	Phase 2	30	NSCLC harboring EGFR mutation (19del, L858R, L861Q, or G719X), stage IIIB/IV or rec, poor ECOG PS (20–74 y with PS 3–4, 75–79 y with PS 2–4, and 80 y or older with PS 1–4), treatment-naive	Gefitinib	17.8
Maemondo et al., 2012⁴⁰ (NEJ003)	Phase 2	31	NSCLC harboring EGFR mutation (19del, L858R, L861Q, or G719X), stage IIIB/IV or rec, 75 y or older, ECOG PS 0–2, treatment-naive	Gefitinib	27.5
Yang et al., 2015⁴⁶ (LUX-lung 2,3,6)	Pooled	75	Lung adenocarcinoma harboring EGFR uncommon mutation (group 1; point mutation or duplications in exon18–21, group 2; de novo T790M, group 3; exon 20 insertion), 18 y or older, stage IIIB/IV, ECOG PS 0–1, treatment-naive	Afatinib	34.7
Cho et al., 2020⁴⁷ (KCSG-LU15-09)	Phase 2	37	NSCLC harboring EGFR mutation (other than 19del, L858R, T790M, or exon 20 insertions), metastatic or rec, 19 y or older, ECOG PS 0–2, EGFR TKI naive	Osimertinib	20.6
Ramalingam et al., 2018⁴⁹ (AURA)	Phase 1	60	NSCLC harboring EGFR mutation (including T790M), locally advanced or metastatic, 18 y or older, WHO PS 0–1, treatment-naive	Osimertinib	19.1

19del, exon 19 deletion; ECOG, Eastern Cooperative Oncology Group; PS, performance status; rec, recurrent disease; TKI, tyrosine kinase inhibitor.